about
Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritisFactor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient miceDesign and Evaluation of Meningococcal Vaccines through Structure-Based Modification of Host and Pathogen MoleculesDimerization of complement factor H-related proteins modulates complement activation in vivoThe development of atypical hemolytic uremic syndrome depends on complement C5Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injuryComplement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction.Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains.Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals.Shiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice.Atypical hemolytic uremic syndrome: telling the difference between H and Y.Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 geneTreatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice.Recurrence of complement factor H-related protein 5 nephropathy in a renal transplantPrevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient micePhagocytosis is the main CR3-mediated function affected by the lupus-associated variant of CD11b in human myeloid cellsComplement component C3 plays a critical role in protecting the aging retina in a murine model of age-related macular degeneration.Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injuryDense deposit disease.Regulating complement in the kidney: insights from CFHR5 nephropathy.Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritisA hybrid CFHR3-1 gene causes familial C3 glomerulopathy.Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency.Annexin A2 Enhances Complement Activation by Inhibiting Factor HLoss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency.Essential role of surface-bound complement factor H in controlling immune complex-induced arthritisDetection of complement activation using monoclonal antibodies against C3d.New approaches to the treatment of dense deposit disease.C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.P2X7 deficiency attenuates renal injury in experimental glomerulonephritis.A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry.Dense deposit disease and C3 glomerulopathyComplement alternative pathway genetic variation and Dengue infection in the Thai populationC3 glomerulopathy: consensus report.Decay-accelerating factor suppresses complement C3 activation and retards atherosclerosis in low-density lipoprotein receptor-deficient mice.Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation.C3 glomerulopathy: clinicopathologic features and predictors of outcome.Complement in human diseases: Lessons from complement deficiencies.C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo.C3 glomerulopathy: a new classification.
P50
Q24615589-1805843D-EF42-4DF9-A5E9-C96C9E28CCB3Q24651118-957D97B4-E489-44B4-A7FC-D289BB55EBC9Q27675010-D8AD7D40-C12B-4390-9E09-0F59A96D47F9Q27676814-397E5000-C603-4339-B34D-31957F2C98EAQ28300378-079680E6-5159-41B0-BC5B-9F3F2B3DA73DQ28511540-1E2D5397-7F02-46CD-AA3E-F358193F9656Q33301870-5C981A1F-1DDB-46C0-B33C-1F2FF9ED2815Q33375335-D5B0A6B7-2AFC-4A88-AD8C-7326E9A03DD0Q33378236-EF8EA4C2-34F7-460F-B929-912A81A67F4DQ33382197-23C8E6FB-DBA0-4608-80D4-0FB00A416C93Q33392073-8A20C2C4-5E74-413D-B0FC-17BBFD485CC8Q33401386-5130AF01-103C-4174-89F2-09ED8ED15D63Q34005720-97B617D3-CBB2-42E5-BBE0-39D71CB926E5Q34467879-C694B57E-33D4-4E69-94D4-7C9D017A881BQ34537391-96CCC1CA-C180-4F5A-8D5E-E39FDD25472DQ34602983-61C80F9B-5B5C-49B5-815E-C3F29CD153B6Q34762966-F64A6C16-F769-44DC-8880-DCC23F058F52Q35097512-6D5E245F-72DF-4F0C-B41B-C3880B642A0EQ35124165-47F35EED-97B3-4843-9384-16B83DC3B1FCQ35532337-EDA0776F-59FE-47CB-951E-92BD4D21AC91Q36034520-C8618385-A2D8-4D9F-9BF4-8A54370DDFE2Q36050943-2DAFF15B-74C1-4746-BA0E-5474C7B17398Q36057084-73A05C36-8670-4D5B-BE96-90F24DED5070Q36495141-E71D9217-8D76-4A0C-BAFD-8C347BE42C2DQ36509318-AB787F8A-6ED6-4ECE-BDFC-87A85B333663Q36714001-BA09D7FA-B765-41A4-B149-3CD99BF2A1F4Q36793448-7CF932C7-E863-4A1A-847A-E72D33D7B9ACQ36860946-FEF549C0-E25F-4E2D-B684-B4E84C070C2FQ36891110-102CC74B-DD2B-45EE-965A-1493925F3877Q37211139-16DCAE96-4055-46BA-942F-9BA279E5C170Q37212087-01414E08-C9C2-4550-9AF1-D0524B4E31E5Q37286653-B5382FD2-F781-4C9C-BC2D-16975D94C768Q37310565-1E517CE8-DA01-47EA-BADE-CFB015EF4326Q37348685-329A60BB-AACE-48EC-8B5C-E1E2590798A9Q37362130-3F2F6039-695A-4DE2-B4C4-39A5F6B3DBE6Q37397572-3C8A0D91-70A6-4530-BAFA-59778FEF2DD0Q37426966-31B13F0F-482D-42D5-A33C-D06117271998Q37501005-4D9108F3-96C1-4C71-8463-B362B28A8620Q37644173-21D17B1B-A6EB-4CC3-9861-D63A6109A6CEQ37770399-DB653EF3-CA34-4C0C-A58C-9D094DA7F9EC
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Matthew C Pickering
@en
Matthew C Pickering
@es
Matthew C Pickering
@nl
Matthew C Pickering
@sl
type
label
Matthew C Pickering
@en
Matthew C Pickering
@es
Matthew C Pickering
@nl
Matthew C Pickering
@sl
altLabel
Matthew Pickering
@en
prefLabel
Matthew C Pickering
@en
Matthew C Pickering
@es
Matthew C Pickering
@nl
Matthew C Pickering
@sl
P106
P21
P31
P496
0000-0002-1153-0192